Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
<p><strong>Background:</strong><br /> The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy.</p><br /> <p><st...
Main Authors: | Neal, D, Metcalfe, C, Donovan, J, Lane, J, Davis, M, Young, G, Dutton, S, Walsh, E, Martin, R, Peters, T, Turner, E, Mason, M, Bollina, P, Catto, J, Doherty, A, Gillatt, D, Gnanapragasam, V, Holding, P, Hughes, O, Kockelbergh, R, Kynaston, H, Oxley, J, Paul, A, Paez, E, Rosario, D, Rowe, E, Staffurth, J, Altman, D, Hamdy, F, Protect Study Group |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2019
|
Similar Items
-
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020) -
Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016) -
The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
by: Young, GJ, et al.
Published: (2020) -
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01) -
The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)